Storage Stability
Mechanism of Action
GLP-1 Component (Semaglutide)
Semaglutide activates GLP-1 receptors in the hypothalamus, reducing hunger signals and increasing satiety. It also slows gastric emptying and reduces glucagon secretion, improving glycemic control.Amylin Component (Cagrilintide)
Cagrilintide is a long-acting amylin/" class="wiki-internal-link">amylin analog that activates amylin receptors in the brainstem, independently reducing food intake and body weight. Amylin also modulates gastric emptying and glucagon secretion through mechanisms distinct from GLP-1.Complementary Dual Pathway
The combination achieves greater weight loss than either component alone because the two peptides act on different receptor systems and brain regions. There is no pharmacodynamic overlap, the effects are additive, not redundant.Research Summary
REDEFINE-1 Phase III Trial
In 3,417 adults with obesity (no diabetes), once-weekly CagriSema 2.4/2.4 mg for 68 weeks produced 22.7% mean body weight loss vs. 2.3% with placebo. This exceeds the ~14.9% seen with semaglutide 2.4 mg alone in the STEP-1 trial.Responder Rates
~75% of CagriSema participants lost ≥15% body weight; ~40% lost ≥25%. These responder rates are substantially higher than single-agent GLP-1 therapies.Safety Profile
GI side effects (nausea, vomiting, diarrhea) were the primary adverse events, consistent with the GLP-1 component. No new safety signals beyond what is known for semaglutide.Calculate your CagriSema dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
Titration Schedule
Both components are titrated upward over 16 weeks to reach the 2.4/2.4 mg maintenance dose. Rapid titration increases GI side effects.Injection
Subcutaneous injection once weekly, same day each week. Rotate injection sites (abdomen, thigh, upper arm).Note
CagriSema is not commercially available as of mid-2026. Research access requires sourcing each component separately and combining per protocol.Storage & Handling
Store both components at 2–8°C. Do not freeze. Both are peptide solutions, protect from light and heat. Can be held at room temperature (<30°C) for up to 28 days once in use (per semaglutide labeling; confirm for cagrilintide per source).
References
- [1]Novo Nordisk. "REDEFINE 1: CagriSema phase 3 trial results." NEJM, 2025.
- [2]Lau J, et al. "Discovery of cagrilintide, a long-acting amylin analog." J Med Chem, 2021.
Ready to dose CagriSema?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
Further reading
CagriSema Titration Protocol (REDEFINE-1)
Read →
More in Weight Loss & Metabolic
View all →